Free Trial

Taysha Gene Therapies (TSHA) Earnings Date, Estimates & Call Transcripts

Taysha Gene Therapies logo
$2.06 -0.21 (-9.25%)
(As of 11/15/2024 ET)

Taysha Gene Therapies Latest Earnings Summary

Latest Q2 2024
Earnings Date
Aug. 12Confirmed
Actual EPS
(Aug. 12)
-$0.09 Beat By $0.01
Consensus EPS
(Aug. 12)
-$0.10

Taysha Gene Therapies announced Q2 2024 earnings on August 12, 2024, reporting an EPS of -$0.09, which topped analysts' consensus estimates of -$0.10 by $0.01. Quarterly revenue was reported to be $1.11 million, below the consensus estimate of $3.62 million. With a trailing EPS of $0.63 and a P/E Ratio of 3.27, Taysha Gene Therapies' earnings are expected to decrease next year, from ($0.34) to ($0.36) per share.

Get Taysha Gene Therapies Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Taysha Gene Therapies and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

TSHA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

TSHA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Taysha Gene Therapies Analyst EPS Estimates

Current Year EPS Consensus Estimate:($0.34) EPS
Next Year EPS Consensus Estimate: ($0.36) EPS

Taysha Gene Therapies Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
8/12/2024Q2 2024-$0.10-$0.09+$0.01-$0.09$3.62M$1.11M      
5/14/2024Q1 2024-$0.11-$0.10+$0.01-$0.10$3.70M$3.41M      
3/19/2024Q4 2023-$0.35+$0.35-$0.22$4.75M$3.60M  
11/14/2023Q3 2023-$0.13-$0.13-$0.67$2.65M$4.75M  
8/14/2023Q2 2023-$0.31-$0.38 -$0.07-$0.38$2.00M$2.40M  
5/11/2023Q1 2023-$0.39-$0.28+$0.11-$0.28-$4.71M  
3/28/2023Q4 2022-$0.41-$0.99 -$0.58-$0.99-$2.50M  

Taysha Gene Therapies Earnings - Frequently Asked Questions

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earning data on Monday, August 12, 2024. Learn more on TSHA's earnings history.

In the previous quarter, Taysha Gene Therapies (NASDAQ:TSHA) reported ($0.09) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.10) by $0.01. Learn more on analysts' earnings estimate vs. TSHA's actual earnings.

The conference call for Taysha Gene Therapies's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Taysha Gene Therapies's latest earnings report can be read online.
Read Transcript

Taysha Gene Therapies (NASDAQ:TSHA) has a recorded annual revenue of $15.45 million.

Taysha Gene Therapies (NASDAQ:TSHA) has a recorded net income of -$111.57 million. TSHA has generated $0.63 earnings per share over the last four quarters.

Taysha Gene Therapies (NASDAQ:TSHA) has a trailing price-to-earnings ratio of 3.27.

Taysha Gene Therapies's earnings are expected to decrease from ($0.34) per share to ($0.36) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:TSHA) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners